The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: -0.01 (-5.00%)
Spread: 0.02 (11.111%)
Open: 0.20
High: 0.00
Low: 0.00
Prev. Close: 0.20
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Tue, 14th Dec 2021 18:01

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Cohort PLC - defence and security markets-focussed technology company - For the six months ended October 31, pretax loss widens to GBP1.7 million from GBP370,000 a year before, due to higher administrative costs more than offsetting a 10% year-on-year increase in revenue to GBP60.0 million from GBP54.4 million. Order intake rose 18% to GBP105.3 million from GBP89.2 million, alongside a record closing order book of GBP285.8 million. Declares interim dividend of 3.85 pence per share, up 10% from 3.50p. Looking ahead, expects Chess order intake and delivery issues to affect the group's performance for the financial year.

----------

BMO Global Smaller Cos PLC - investment firm focused on on a portfolio of global smaller companies - As at October 31, net asset value per share increases 37% year-on-year to 183.62 pence from 134.49p. NAV total return for the period is 5.6%, compared to a 4.3% return from the benchmark, comprising 30% Numis UK Smaller Companies ex investment companies Index and 70% MSCI World All Countries ex UK Small Cap Index. Declares interim dividend of 0.57p per share, up 3.6% from 0.55p a year prior.

----------

Henderson Diversified Income Trust PLC - Janus Henderson managed trust seeking income and capital growth - As at October 31, net asset value per share increases 1.8% to 91.42 pence from 89.83p the same date a year before. NAV total return at 1.9%, compared to a 1.3% return from its benchmark, comprising 60% Global High Yield Credit, 25% Global Investment Grade Corporate Credit and 15% European Loans. Dividend per share for the six month period remains in line at 4.40p.

----------

GRC International Group PLC - Ely, England-based products and services for IT governance, risk management and compliance - For the six months ended September 30, pretax loss narrows to GBP492,000 from GBP1.5 million the same period a year before, on revenue which grew 22% year-on-year to GBP6.6 million from GBP5.4 million. Billings increases 27% to GBP7.1 million from GBP5.6 million, with the Software-as-a-Service rising on a boost in customers amid high demand. Looking ahead, expects strong trading momentum to continue into second half of the financial year.

----------

Miton UK MicroCap Trust PLC - investment firm focused on company's with market cap of less than GBP150 million - Net asset value per share as at October 31 increases 55% year-on-year to 96.67 pence from 62.32p. However for the six month period, NAV total return declined 7.8%, compared to 1.4% rise from the Numis 1000 Index.

----------

Begbies Traynor Group PLC - corporate restructuring specialist - For the six months ended October 31, pretax profit hikes to GBP2.7 million from GBP451,000 the same period a year before, on revenue which grew 39% year-on-year to GBP52.3 million from GBP37.5 million, through new acquisitions including MAF Finance and Fernie Greaves Chartered Surveyors and in comparison to a prior period affected by the lockdown. Declares interim dividend of 1.1 pence per share, up 10% from 1.0p the prior year. Looking ahead, expects annual results to be in line with market expectations.

----------

Surface Transforms PLC - Liverpool-based ​​carbon fibre reinforced ceramic brake discs maker - Expects revenue for 2021 to be below GBP3 million, and significantly short of market expectations, due to a results of delays in the final commissioning of the upscaled production capacity at Knowsley. Although these capacity issues have been narrowed down to one complex furnace, which is on-track to be resolved immediately, Surface Transforms is unlikely to recover the sales gap in 2021, due to December being "a short month".

----------

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - For the six months ended September 30, pretax loss narrows to GBP449,022 from GBP475,874 the same period a year before, as lower costs more than offset revenue dropping to GBP50,000 from GBP195,550. Revenue came from the second instalment of the upfront payment from Oxilio on the full licensing agreement for NXP001. Company plans to raise GBP1.7 million through a subscription of 110.0 million shares by Lanstead Capital Investors LP at 1.5 pence each, the proceeds of which will go towards the development of NXP002 and NXP004.

----------

Trellus Health PLC - White Plains, New York-based digital health platform for complex chronic conditions - For 2021, company expects to incur a loss before interest, tax, depreciation and amortisation of USD5.9 million, on revenue of USD25,000. As at December 31, year-end cash is expected to be at least USD30 million, rising above market expectations.

----------

Yourgene Health PLC - molecular diagnostics firm - For the six months ended September 30, pretax loss narrows to GBP306,000 from GBP2.6 million the same period a year prior, due to revenue more than doubling to GBP17.5 million from GBP8.2 million through a sharp rise in Genomic Services through the high volume of Covid-19 testing services. Looking ahead, expects revenue for the financial year to further exceed market expectations. In addition, Yourgene wins a contract for the provision of genetic sequencing services by the UK Health Security Agency, which will run until March 31.

----------

Majedie Investments PLC - London-based investment trust - As at September 30, net asset value per share increases 16% year-on-year to 287.1 pence from 247.7p the same date the year before. For the annual period, net asset value total return was 20.6%. compared to the FTSE All-Share Index, which returned 27.9% and the MSCI All Country Index, which returned 22.1%. Declares final dividend of 7.0 pence per share, in line with year before.

----------

Jupiter Green Investment Trust PLC - investment firm focused on companies which have a significant focus on environmental solutions - Net asset value per share as at September 30 increased to 277.38 pence from 258.24p at the end of March. NAV total return is 4.6%, reflecting an underperformance against the MSCI World Small Cap Total Return Index, which returned 6.7%.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

Wednesday 13 March 
abrdn China Investment Co LtdGM re liquidation
Safestore Holdings PLCAGM
Wincanton PLCGM re takeover by CEVA Logistics
Thursday 14 March 
Angus Energy PLCGM
Bank of Georgia Group PLCGM re acquisition of Ameriabank CJSC
Blackrock Sustainable American Income Trust PLCAGM
Friday 15 March 
BlackRock Energy & Resources Income Trust PLCAGM
Chrysalis Investments LtdAGM
Quantum Exponential Group PLCGM re delisting from AQSE
TruSpine Technologies PLCAGM (adjourned 2022)
United Oil & Gas PLCGM re fundraise and share sub-division
Monday 18 March 
MGC Pharmaceuticals LtdGM re change of company name to Argent Biopharma
Schroder European Real Estate Investment Trust PLCAGM
Tuesday 19 March 
BlackRock Throgmorton Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Eco Animal Health Group PLCGM re share buybacks
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Nuformix PLCAGM
Scirocco Energy PLCGM re requisitioned resolution to implement cash strategy
Various Eateries PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis.

Read more
18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year.

Read more
17 Aug 2023 15:43

UK shareholder meetings calendar - next 7 days

Friday 18 August 
Adams PLCAGM
ME Group International PLCGM re proposed share buyback
Oxford BioDynamics PLCGM re placing
Pathfinder Minerals PLCGM re disposal of the subsidiary
Monday 21 August 
Calculus VCT PLCAGM
Home REIT PLCGM re changes to the investment policy
Tuesday 22 August 
Cake Box Holdings PLCAGM
ReNeuron Group PLCAGM
RUA Life Sciences PLCAGM
Smoove PLCAGM
STM Group PLCAGM
Wednesday 23 August 
Brandshield Systems PLCAGM
James Latham PLCAGM
LifeSafe Holdings PLCGM re shareholder circular
Momentum Multi-Asset Value Trust PLCGM re appointment of the liquidators
Sovereign Metals LtdGM re share placement options
Thor Energy PLCGM re proposed share consolidation
Thursday 24 August 
Ananda Developments PLCAGM
Concurrent Technologies PLCAGM
CyanConnode Holdings PLCAGM
Nuformix PLCAGM
Oryx International Growth Fund LtdAGM
ThomasLloyd Energy Impact Trust PLCAGM
ThomasLloyd Energy Impact Trust PLCGM re market purchases of its own ordinary shares
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 May 2023 12:45

Nuformix loss narrows; near-term goal to focus on NXP002 asset

(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Apr 2023 12:14

Nuformix raises GBP70,000 to fund NXP002 programme

(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Feb 2023 12:12

Nuformix progresses NXP002 trial after acquiring human tissue

(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Read more
13 Dec 2022 14:54

Nuformix interim loss virtually flat as continues work on drugs

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.

Read more
23 Sep 2022 21:02

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Aug 2022 16:01

UK shareholder meetings calendar - next 7 days

Friday 19 August 
Braemar Shipping Services PLCAGM
Citius Resources PLCAGM
Next Fifteen Communications Group PLCGM re acquisition of M&C Saatchi
Volex PLCAGM
Monday 22 August 
African Pioneer PLCAGM
Argentex Group PLCAGM
Nostrum Oil & Gas PLCGM operational update
Ondo InsurTech PLCAGM
Sabien Technology Group PLCGM re broker option
Scottish Investment Trust PLCGM re recombination of assets with JPMorgan Global Growth & Income plc
Trackwise Designs PLCAGM
Tuesday 23 August 
Bezant Resources PLCAGM
Livermore Investments Group LtdAGM
Xtract Resources PLCAGM
Wednesday 24 August 
Amur Minerals CorpGM subsidiary sale
Creightons PLCAGM
Goldstone Resources LtdAGM
Thursday 25 August 
Ince Group PLCGM fundraising
McBride PLCGM increase in borrowing limit
NatWest Group PLCGM re approval of special dividend
Nuformix PLCAGM
Triple Point Energy Efficiency Infrastructure Co PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Aug 2022 11:14

IN BRIEF: Nuformix shares rise on tolerability studies completion

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.